BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18636014)

  • 1. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
    Yousem SA; Nikiforova M; Nikiforov Y
    Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
    De Oliveira Duarte Achcar R; Nikiforova MN; Yousem SA
    Am J Clin Pathol; 2009 May; 131(5):694-700. PubMed ID: 19369630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
    Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
    Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E Mutations in Endometrial Adenocarcinoma.
    He M; Breese V; Hang S; Zhang C; Xiong J; Jackson C
    Diagn Mol Pathol; 2013 Mar; 22(1):35-40. PubMed ID: 23370429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
    Kang S; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
    Gynecol Oncol; 2007 Jun; 105(3):662-6. PubMed ID: 17360030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
    Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
    J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF and KRAS mutations in prostatic adenocarcinoma.
    Cho NY; Choi M; Kim BH; Cho YM; Moon KC; Kang GH
    Int J Cancer; 2006 Oct; 119(8):1858-62. PubMed ID: 16721785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
    Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
    Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
    Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
    Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
    PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
    Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
    Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
    Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.